SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trial

Sammy Huygens, Quincy Hofsink, Inger S Nijhof, Abraham Goorhuis, Arnon P Kater, Peter AW te Boekhorst, Francis Swaneveld, Věra MJ Novotný, Susanne Bogers, Matthijs RA Welkers, Grigorios Papageorgiou, Bart J Rijnders, Jarom Heijmans
doi: https://doi.org/10.1101/2022.04.04.22273314

Article usage

Article usage: April 2022 to November 2024

AbstractFullPdf
Apr 2022168217256
May 2022182836
Jun 20221551128
Jul 2022952113
Aug 2022841818
Sep 202264111
Oct 202266147
Nov 202254212
Dec 202227211
Jan 20233826
Feb 20232427
Mar 20232732
Apr 202331110
May 20232635
Jun 20231242
Jul 2023613
Aug 202329105
Sep 20231744
Oct 20231334
Nov 20231843
Dec 2023924
Jan 20241605
Feb 202415410
Mar 20242133
Apr 20243025
May 20242028
Jun 20243235
Jul 20242837
Aug 20243147
Sep 20242844
Oct 20244187
Nov 20241506
Back to top
Posted April 05, 2022.
Download PDF

Supplementary Material

Data/Code
Email
SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trial
Sammy Huygens, Quincy Hofsink, Inger S Nijhof, Abraham Goorhuis, Arnon P Kater, Peter AW te Boekhorst, Francis Swaneveld, Věra MJ Novotný, Susanne Bogers, Matthijs RA Welkers, Grigorios Papageorgiou, Bart J Rijnders, Jarom Heijmans
medRxiv 2022.04.04.22273314; doi: https://doi.org/10.1101/2022.04.04.22273314
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area